Showing 711-720 of 19240 results for "".
Understanding the Complex Link Between PIF, Inhaler Choice, and COPD Outcomes
https://reachmd.com/programs/frontlines-copd/understanding-the-complex-link-between-pif-inhaler-choice-and-copd-outcomes/35545/Since suboptimal peak inspiratory flow (PIF) seems to be associated with a higher risk of hospital readmissions and mortality among patients with COPD, it’s now more important than ever to create a clinically relevant definition. Tune in to hear Dr. Jill Ohar discuss this unmet need as well as the iPracticing Physicians Speak Out: CME As We Need It - Part One
https://reachmd.com/programs/lifelong-learning/practicing-physicians-speak-out-cme-as-we-need-it-part-one/6032/When CME content is designed and developed, it is based on educational needs assessments. But needs vary across the spectrum of physicians and types of practices they engage in. What kind of CME is most needed? What are the shortcomings of current delivery modes, as well as CME types? How can theyLife for a Child
https://reachmd.com/programs/clinicians-roundtable/life-for-a-child/1844/Join Dr. Graham Ogle from Sydney, Australia, as he discusses the International Diabetes Federation Life for a Child Program.DKA in Focus: What the New Consensus Means for Practice
https://reachmd.com/programs/cme/dka-new-consensus-practice/50979/If widespread use of continuous ketone monitoring (CKM) devices is to be safe and effective in reducing the occurrence of diabetic ketoacidosis (DKA), it is important to establish clear ketone thresholds which notify CKM users when action on their part is required. In preparation for availability anInvestigator Perspectives on Treating Patients in a Ph2 NSCLC Trial
https://reachmd.com/programs/project-oncology/investigator-perspectives-on-treating-patients-in-a-ph2-nsclc-trial/26564/High c-MET protein overexpression is a MET aberration2,3 seen in about 1 in 7 or 14% of patients with EGFR wild-type non-squamous non-small cell lung cancer (NSCLC) tumors. Telisotuzumab vedotin-tllv (Teliso-V) is a first-in-class, c-Met protein-directed antibody-drug conjugate that was studied in tAnalyzing Clinical Trial Data: Part 1
https://reachmd.com/programs/cme/Analyzing-Clinical-Trial-Data-Part-1/35971/Catch up on the latest information on the management of macular telangiectasia type 2 (MacTel) with a new encapsulated cell therapy, revakinagene taroretcel.Analyzing Clinical Trial Data: Part 2
https://reachmd.com/programs/cme/Analyzing-Clinical-Trial-Data-Part-2/35972/Catch up on the latest information on the management of macular telangiectasia type 2 (MacTel) with a new encapsulated cell therapy, revakinagene taroretcel.Epinephrine Evolution: New Developments in Food Allergy Treatment
https://reachmd.com/programs/frontlines-food-allergies/epinephrine-evolution-new-developments-in-food-allergy-treatment/26316/Here’s how nasal and sublingual epinephrine may help address some of the common challenges associated with the traditional injection type.The Future Is Biochemical
https://modernaesthetics.com/topics/practice-development/the-future-is-biochemical/35417/This frontier is being shaped by a category I call “biochemical cues”: modalities like exosomes, peptides, growth factors, PDRN (polydeoxyribonucleotide), and other regenerative approaches, which tap into the body’s own healing and repair mechanisms to deliver profound results.Anemia in the Long Term Care Setting
https://reachmd.com/programs/advances-in-long-term-care-medicine/anemia-in-the-long-term-care-setting/4356/What are the various types of anemia found in long-term care settings, and which types are the most common? What are some of the underlying causes of both chronic and acute anemia? Dr. Charles Cefalu, clinical professor and chief of the section of geriatric medicine at Louisiana State University Hea